Oxycodone findings and CYP2D6 function in postmortem cases.
Adolescent
Adult
Aged
Analgesics, Opioid
/ blood
Cytochrome P-450 CYP2D6
/ genetics
DNA Copy Number Variations
Female
Forensic Genetics
Genotype
High-Throughput Nucleotide Sequencing
Humans
Male
Middle Aged
Morphinans
/ blood
Oxycodone
/ blood
Pharmacogenomic Testing
Phenotype
Polymorphism, Single Nucleotide
Young Adult
CYP2D6 polymorphism
Forensic Toxicology
Metabolite ratios
Oxycodone related deaths
Pharmacogenetics
Postmortem toxicology
Journal
Forensic science international. Genetics
ISSN: 1878-0326
Titre abrégé: Forensic Sci Int Genet
Pays: Netherlands
ID NLM: 101317016
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
21
07
2020
revised:
04
12
2020
accepted:
21
03
2021
pubmed:
3
4
2021
medline:
18
8
2021
entrez:
2
4
2021
Statut:
ppublish
Résumé
Genetic disposition can cause variation in oxycodone pharmacokinetic characteristics and decrease or increase the expected clinical response. In forensic medicine, determination of cause of death or assessing time between drug intake and death can be facilitated by knowledge of parent and metabolite concentrations. In this study, the aim was to investigate if CYP2D6 genotyping can facilitate interpretation by investigating the frequency of the four CYP2D6 phenotypes, poor metabolizer, intermediate metabolizer, extensive metabolizer, and ultra-rapid metabolizer in postmortem cases, and to study if the CYP2D6 activity was associated with a certain cause of death, concentration, or metabolic ratio. Cases positive for oxycodone in femoral blood (n = 174) were genotyped by pyrosequencing for CYP2D6*3, *4, and *6 and concentrations of oxycodone, noroxycodone, oxymorphone, and noroxymorphone were determined by LC-MS/MS (LLOQ 0.005 µg/g). Digital droplet PCR was used to determine the copy number variation for CYP2D6*5. Cases were categorized by cause of death. It was found that poor and intermediate CYP2D6 metabolizers had significantly higher oxycodone and noroxycodone concentrations compared to extensive and ultra-rapid metabolizers. CYP2D6 phenotype were equally distributed between cause of death groups, showing that no phenotype was overrepresented in any of the cause of death groups. We also found that the concentration ratio between oxymorphone and oxycodone depended on the CYP2D6 activity when death was unrelated to intoxication. In general, a low metabolite to parent ratio indicate an acute intake. By using receiver operating characteristic (ROC) analysis, we conclude that an oxymorphone/oxycodone ratio lower than 0.075 has a high sensitivity for separating intoxications with oxycodone from other intoxications and non-intoxications. However, the phenotype needs to be known to reach a high specificity. Therefore, the ratio should not be used as a biomarker on its own to distinguish between different causes of death but needs to be complemented by genotyping.
Identifiants
pubmed: 33799050
pii: S1872-4973(21)00048-X
doi: 10.1016/j.fsigen.2021.102510
pii:
doi:
Substances chimiques
Analgesics, Opioid
0
Morphinans
0
noroxycodone
95Q949779D
Oxycodone
CD35PMG570
Cytochrome P-450 CYP2D6
EC 1.14.14.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
102510Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.